License Exemplifies Broad Applicability of Anesiva's Needle-Free Technology
SOUTH SAN FRANCISCO, Calif., and OXFORD, England, Aug. 30 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited today announced that they have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva's drug delivery technology into its needle-free, intradermal delivery system for glucagon, a hormone commonly used for the treatment of hypoglycemia associated with Type 1 and Type 2 diabetes.
"This agreement exemplifies the potential of our technology to transform the delivery of proteins, peptides and small molecules in a clinically meaningful way that is also safer, more comfortable and more convenient," said John P. McLaughlin, chief executive officer of Anesiva. "We intend to seek other opportunities for licensing this important platform technology."
"Patients experiencing a hypoglycemic condition may lose consciousness,
and if not treated quickly, can suffer short and long-term cerebral
damage," remarked Fred Cornhill, Director of Particle Therapeutics.
"Current methods of treating diabetic hypoglycemia require the mixing of
glucagon powder with a sterile saline solution, followed by needle
injection. At present, an estimated 1-1.5 million kits with glucagon powder
are sold annually in the U.S. and Europe. Those with Type 1 diabetes
typically have at least one to eight such events per year, requiring
intervention of another person or summoning of medical assistance. Type 2,
insulin dependent diabetes patients have fewer incidents, but, with lower
glycemic targets, the incidence of hypoglycemia, requiring third party
intervention is increasing. Par
|SOURCE Anesiva, Inc.|
Copyright©2007 PR Newswire.
All rights reserved